RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Joseph Gibbons to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications Joseph Gibbons has written about Antibodies, Viral.
Joseph Gibbons
Connection Strength
0.141
Antibodies, Viral
  1. Altmann DM, Reynolds CJ, Joy G, Otter AD, Gibbons JM, Pade C, Swadling L, Maini MK, Brooks T, Semper A, McKnight ?, Noursadeghi M, Manisty C, Treibel TA, Moon JC, Boyton RJ. Persistent symptoms after COVID-19 are not associated with differential SARS-CoV-2 antibody or T cell immunity. Nat Commun. 2023 08 23; 14(1):5139.
    View in: PubMed
    Score: 0.049
  2. Gokani B, Sacoor S, Leisegang GR, Ogunkolade W, Bibi A, Grigoriadou S, Pade C, Gibbons J, Senusi A, Fortune F. Beh?et's patients' response to COVID-19 vaccination. Clin Immunol. 2023 10; 255:109700.
    View in: PubMed
    Score: 0.049
  3. Usai C, Gibbons JM, Pade C, Li W, Jacobs SRM, McKnight ?, Kennedy PTF, Gill US. The ?-NGF/TrkA Signalling Pathway Is Associated With the Production of Anti-Nucleoprotein IgG in Convalescent COVID-19. Front Immunol. 2021; 12:813300.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support